GEN İlaç Chairman: Innovative Drug from Turkey Could Exceed $1 Billion

Abidin Gülmüş, Chairman of GEN İlaç, made statements about the pharmaceutical sector on the program 'Health on the Stock Exchange' broadcast on Dünya Gazetesi TV. Gülmüş emphasized that artificial intelligence accelerates drug development processes, noting that Turkey has achieved significant localization in drug production, but the main goal is to develop high value-added innovative products. Gülmüş stated that an innovative drug emerging from Turkey could surpass the $1 billion threshold. He reported that the company is conducting clinical studies for Parkinson's and Alzheimer's treatments and has made significant progress in these areas. Additionally, Gülmüş shared international growth targets with a new production facility to be established in Azerbaijan, saying this investment will increase the company's competitiveness in the global market. GEN İlaç continues to strengthen its local production capacity while accelerating its innovative drug development efforts. This is not investment advice.